PHNM logo

Pharmanutra BATS-CHIXE:PHNM Stock Report

Last Price

€62.60

Market Cap

€522.1m

7D

0%

1Y

-12.1%

Updated

13 Sep, 2023

Data

Company Financials +

Pharmanutra S.p.A.

BATS-CHIXE:PHNM Stock Report

Market Cap: €522.1m

PHNM Stock Overview

A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. More details

PHNM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance2/6
Financial Health5/6
Dividends1/6

My Notes

Capture your thoughts, links and company narrative

Pharmanutra S.p.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharmanutra
Historical stock prices
Current Share Price€62.60
52 Week High€69.60
52 Week Low€51.70
Beta0.26
1 Month Change0%
3 Month Change2.96%
1 Year Change-12.08%
3 Year Changen/a
5 Year Changen/a
Change since IPO-11.33%

Recent News & Updates

Recent updates

Shareholder Returns

PHNMGB Personal ProductsGB Market
7D0%-2.0%-2.2%
1Y-12.1%19.7%2.4%

Return vs Industry: PHNM underperformed the UK Personal Products industry which returned -5.9% over the past year.

Return vs Market: PHNM underperformed the UK Market which returned -2.4% over the past year.

Price Volatility

Is PHNM's price volatile compared to industry and market?
PHNM volatility
PHNM Average Weekly Movementn/a
Personal Products Industry Average Movement3.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.5%
10% least volatile stocks in GB Market2.6%

Stable Share Price: PHNM has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine PHNM's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200390Roberto Lacortewww.pharmanutra.it

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, Africa, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company’s products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2.

Pharmanutra S.p.A. Fundamentals Summary

How do Pharmanutra's earnings and revenue compare to its market cap?
PHNM fundamental statistics
Market cap€522.13m
Earnings (TTM)€14.05m
Revenue (TTM)€93.22m

37.2x

P/E Ratio

5.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHNM income statement (TTM)
Revenue€93.22m
Cost of Revenue€48.64m
Gross Profit€44.59m
Other Expenses€30.54m
Earnings€14.05m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.46
Gross Margin47.83%
Net Profit Margin15.07%
Debt/Equity Ratio52.8%

How did PHNM perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

55%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/13 17:16
End of Day Share Price 2023/06/16 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmanutra S.p.A. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrea RandoneIntermonte SIM S.p.A.
Giorgio TavoliniIntermonte SIM S.p.A.
Daniele AlibrandiStifel, Equities Research